Secnidazole

Summary

Secnidazole (CHEMBL498847) is an approved small-molecule antiprotozoal drug (ATC P01AB07); indicated across 4 conditions including bacterial vaginosis and trichomoniasis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: P01AB07
• Indications: 4 conditions
• Clinical trials: 10
• Chemistry: 185.18 Da · C7H11N3O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL498847
Name	Secnidazole
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	71815
ChEBI	CHEBI:140628
ATC	P01AB07
Molecular formula	C7H11N3O3
Molecular weight	185.18
InChIKey	KPQZUUQMTUIKBP-UHFFFAOYSA-N

SMILES: CC1=NC=C(N1CC(C)O)[N+](=O)[O-]

IUPAC name: 1-(2-methyl-5-nitroimidazol-1-yl)propan-2-ol

ChEBI definition: A C-nitro compound that is 5-nitroimidazole in which the hydrogens at positions 1 and 2 are replaced by 2-hydroxypropyl and methyl groups, respectively. It is a drug used for the treatment of trichomoniasis caused by Trichomonas vaginalis.

Pharmacological roles (ChEBI): epitope, antiprotozoal drug, antibacterial agent.

Also known as: Deprozol, Flagentyl, NSC-759812, Ornidazole metabolite m4, PM-185184, RP 14539, RP-14539, Secnidal, Secnidazol, Secnidazole, Secnidazole anhydrous, Solosec

Patent coverage: 644 distinct patent families (1,851 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Serine-protein kinase ATM, Mitogen-activated protein kinase 1.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
MAPK1	5.3	Potency	5012	nM	CHEMBL_ACT_4725558
ATM	5.15	Potency	7080	nM	CHEMBL_ACT_4863360

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial vaginosis	4	MONDO:0005316	EFO:0003932
trichomoniasis	4	MONDO:0002154	DOID:1947
amebiasis	4	MONDO:0005644	EFO:0007144
vaginal discharge	3	MONDO:0002770	EFO:0009365

Clinical trials

Total trials: 10.

Phase distribution

Phase	Trials
PHASE3	5
PHASE4	2
PHASE2/PHASE3	1
PHASE1/PHASE2	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06261840	PHASE4	RECRUITING	Refining Treatment Options for Trichomonas Vaginalis Infection: A Comparative Analysis of Metronidazole and Secnidazole
NCT03937869	PHASE4	COMPLETED	Evaluate the Safety of a Single Oral Dose of Solosec™ (Secnidazole) 2g for the Treatment of Adolescent Girls With BV
NCT01733966	PHASE3	TERMINATED	A Multicentre, Randomized as a Double Blind Study, Triple Placebo, Comparative of the Efficacy and Safety of an Association Secnidazol-Ciprofloxacin Compared With Amoxicillin-Clavulanic Acid for the Treatment of Uncomplicated Episode of Diverticular Sigmoïditis Among Adults
NCT02111629	PHASE3	COMPLETED	Safety and Clinical and Microbiological Efficacy of the Combination of Fluconazole and Secnidazole for the Treatment of Symptomatic Vaginal Discharge
NCT02418845	PHASE3	COMPLETED	A Phase 3 Study of SYM-1219 Treatment of Women and Post-Menarchal Adolescent Girls With Bacterial Vaginosis
NCT02452866	PHASE3	COMPLETED	Open-Label Study to Evaluate Safety of A Single Dose of SYM-1219
NCT03935217	PHASE3	COMPLETED	A Phase 3 Study of Solosec® for the Treatment of Trichomoniasis
NCT05033743	PHASE2/PHASE3	COMPLETED	Suppressive Antibacterial Therapy With Once-Weekly Secnidazole Granules to Prevent Recurrent Bacterial Vaginosis; A Pilot Study
NCT01019083	PHASE1/PHASE2	COMPLETED	Studies of Immune Responses to Orally Administered Vaccines in Developing Country
NCT02147899	PHASE2	COMPLETED	A Phase 2 Study of SYM-1219 to Treat Bacterial Vaginosis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).